RALOXIFENE GxP Raloxifene hydrochloride 60 mg tablets, blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

raloxifene hydrochloride, Quantity: 60 mg

Verfügbar ab:

MedTAS Pty Ltd

INN (Internationale Bezeichnung):

Raloxifene hydrochloride

Darreichungsform:

Tablet, film coated

Zusammensetzung:

Excipient Ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; glycine; colloidal anhydrous silica; polysorbate 80; povidone; titanium dioxide; hypromellose; Carnauba Wax; macrogol 400

Verabreichungsweg:

Oral

Einheiten im Paket:

28 tablets

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Produktbesonderheiten:

Visual Identification: White to off-white, oval, biconvex, film coated tablets with 'C' on one side and '12' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2014-01-14